1. Confirmed diagnosis of a comorbidity known to affect gastric motility (i.e., Parkinson\'s Disease, Type 1 or 2 Diabetes).

2. Medications in the last 3 months known to impact gastric motility.

3. Any Gastric Surgery

4. Pregnancy or lactation, determined by pregnancy test at timeof enrolment.

5. Known allergy to adhesives and/or skin sensitivities, or any allergy to liraglutide or any components of the liraglutide/Saxenda formulation, or known hypersensitivity to Spirulina, egg, milk or wheat allergens

6. Use of GLP-1 agonist and/or on regular insulin in the past 3months.

7. History of gastroduodenal dysfunction and/or meets the ROME IV symptom criteria for a gastroduodenal disorder of gut-brain interaction (functional dyspepsia, chronic nausea and vomiting syndrome, cyclic vomiting syndrome, rumination syndrome, cannabinoid hyperemesis syndrome, or a belching disorder).

8. History of peptic ulcer, pancreatitis, cholelithiasis, choledocholithiasis, History of kidney or hepatic dysfunction

9. History of psychiatric disturbance requiring medication in the year before enrolment, any history of suicide attempt or eating disorder

10. History of Type II Diabetes or glucose intolerance (treated or untreated)

11. History of cancer other than basal cell skin cancer, and patients with personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)

12. History of angioedema or urticaria disorder

13. History of cardiac disorder or arrhythmia

14. Any tobacco, vaping or cannabinoid use in the 30 days prior to study